Recently, the integration of immunotherapy into the adjuvant setting for NSCLC with programmed death-ligand 1 (PD-L1) expression ≥50% (7), as well as targeted therapies for epidermal growth factor receptor (EGFR)-mutated disease (8) and anaplastic lymphoma kinase (ALK) fusions (9), has significantly improved survival outcomes in patients undergoing surgical treatment. Here, ALK is linked to non-small cell lung carcinoma.